THE DEMO PROJECT





Sexual Risk Behaviors and Sexually Transmitted Infections Among MSM participating in the US PrEP Demo Project

SE Cohen, E Vittinghoff, SS Philip, S Doblecki-Lewis, O Bacon, W Chege, R Elion, S Buchbinder, MA Kolber, A Liu

> World HIV & STD Congress, 2015 Brisbane, Australia

The views expressed herein do not necessarily reflect the official policies of the City and County of San Francisco; nor does mention of the San Francisco Department of Public Health imply its endorsement.

Disclosures

- The US PrEP Demonstration Project was funded by the NIH
- Gilead Sciences provided study drug and supported drug level testing for this project

Background



- Several RCTs have shown that daily oral TDF/FTC is effective in preventing HIV infection¹⁻⁴
- Whether individuals taking PrEP will increase sexual risk behavior (i.e. risk compensation) is unclear
- PrEP demonstration projects, in which clients are educated about the efficacy of TDF/FTC and take it in an open-label fashion, are optimal settings for assessing whether risk compensation occurs

¹Grant NEJM 2010; ²Baeten NEJM 2012; ³Thigpen NEJM 2012; ⁴Choopanya Lancet 2013

The Demo Project

- Multisite, open-label PrEP Demonstration Project in MSM and transgender women in two STD clinics and a community health center in the US
- · Key objectives
 - PrEP uptake^{1,2}
 - Adherence and retention^{1,3}
 - Safety and tolerability³
 - HIV incidence and resistance³
 - Sexual behaviors
 - STI incidence

Pro-exposure
Prophylasis (PEP)
for HIV prevention

¹Cohen S CROI 2014, ²Cohen JAIDS 2015; ³Liu IAS 2015

Methods: Demo Project Sites

San Francisco City Clinic (N=300)



Whitman Walker Health,
Washington, DC

Miami-Dade County
Downtown STD clinic (N=157)





Annual HIV seroconversion rate among MSM >2% across clinics

Methods: Eligibility and follow-up

- HIV-negative MSM and transgender women enrolled between Oct 2012 - Jan 2014
- Behavioral risk criteria (last 12 mo):
 - Condomless anal sex with 2+ partners
 - 2+ episodes of anal sex with HIV+ partner
 - Self-reported diagnosis of syphilis, rectal gonorrhea or rectal chlamydia
- CrCl ≥ 60 ml/min, negative/trace protein on urine dipstick, HbSAg negative
- · Participants offered up to 48 weeks of TDF/FTC PrEP
- Followed at weeks 4, 12, 24, 36 and 48 for HIV/STI testing, counseling, clinical monitoring, drug level testing and PrEP dispensation

Methods: Assessment of sexual risk

- · At screening and quarterly visits, participants completed an interviewer administered questionnaire regarding sexual and drug use behaviors, HIV risk perception, and serosorting intentions
- · Composite measure of sexual risk assessed using modified "San Diego Early Test" (mSDET) Score1:

In the last 3 months -

- Any condomless receptive anal sex (CRAS) with HIV+ partner (3 points)
- Combination of any CRAS plus ≥ 2 male anal sex partners (3
- ≥ 5 male anal sex partners (2 points)

¹Hoenigl CID 2015


Methods: Statistical analysis

- Trends over time in absolute numbers of sexual partners and episodes, by partner HIV status, position and condom use were assessed using orthogonal contrasts in the weekly means, based on a Poisson regression model with robust standard errors to account for clustering by participant of the repeated outcomes.
- Covariate effects on changes in the mSDET scores were also estimated using Poisson models with robust SEs, using interactions between each covariate and an indicator for follow-up vs baseline.
- Heterogeneity across weeks in positivity of STI tests was assessed using logistic models with robust SEs to account for clustering.


Baseline characteristics of enrolled participants (N=557)

Characteristic	%
Age (median)	35 years with 20% <25 years
Race/ethnicity White Latino Black Other	48% 35% 7% 10%
Gender Male Transgender	98% 1.3%
Education level ≤ High School Some college or higher	15% 85%
Any recreational drug use Popper, cocaine, meth, or club drug use	74% 58%
Number of anal sex partners, past 3 months (mean)	11
Condomless receptive anal sex, past 3 mo	67%
HIV+ primary partner	24%
Lab confirmed STI (GC, CT, syphilis) at baseline	26%


Anal Sex Partners, by HIV status and condom use



Insertive and Receptive Anal Sex Episodes, by condom use




Serosorting Practices




Serosorting Intentions:


"When having sex with an HIV-positive partner I would..."




HIV Risk Perception



Change in overall risk as measured by mSDET risk score



Results: STI positivity



50.9% of participants had at least one STI during follow-up Overall STI incidence (90/100 person years) stable across quarterly intervals (P>0.1) As expected, >75% of GC and >85% of CT infections were asymptomatic

Limitations

- Sexual risk behavior collected by intervieweradministered questionnaire, subject to social desirability bias
- Observational cohort with no comparison group
- Non-differential follow-up by level of risk could bias results
- Blacks and transgender women underrepresented
- Results may not generalize to broader MSM populations in these or other US cities, international settings
- Demo Project provided risk reduction counseling at each quarterly visit, may not apply in settings in which counseling not offered

Conclusions

- By multiple measures, including number of anal sex partners, episodes and a composite sexual risk score, sexual risk behavior was stable or declining over the course of the study.
- While self-reported behaviors did not reflect a change in seroadaptive practice, intentions around seroadaptation did change; over time, this could have implications for sexual networks and STI risk.
- 50% of participants had a variation in risk score from visit to visit – re-assessing risk among clients using PrEP is important.
- High incidence of STIs reflects importance of comprehensive sexual health support and quarterly STI screening, including testing at extragenital sites, for MSM taking PrEP.

Acknowledgements

San Francisco
Albert Liu
Susan Buchbinder
Oliver Bacon
Robert Blue
Nikole Trainor
Susan Philip
Tim Matheson
Erin Andrew

Miami Michael Kolber Susanne Doblecki-Lewis Jose Castro Yannine Estrada Daniel Feaster Gabriel Cardenas

<u>DC</u> Rick Elion Megan Coleman Justin Schmandt Other Co-Investigators Eric Vittinghoff Peter Anderson Teri Liegler K. Rivet Amico Robert Grant

NIAID Wairimu Chege Cherlynn Mathias David Burns Michelle Wildman

NIMH Michael Stirratt Chris Gordon

DF/Net Brian Postle

Gilead Jim Rooney Keith Rawlings Study participants









D Sar Fondato

mSDET Score (distribution and mean) over time

